SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

Sean G. Buchanan, Jorg Hendle, Patrick S. Lee, Christopher R. Smith, Pierre Yves Bounaud, Katti A. Jessen, Crystal M. Tang, Nanni H. Huser, Jeremy D. Felce, Karen J. Froning, Marshall C. Peterman, Brandon E. Aubol, Steve F. Gessert, J. Michael Sauder, Kenneth D. Schwinn, Marijane Russell, Isabelle A. Rooney, Jason Adams, Barbara C. Leon, Tuan H. DoJeff M. Blaney, Paul A. Sprengeler, Devon A. Thompson, Lydia Smyth, Laura A. Pelletier, Shane Atwell, Kevin Holme, Stephen R. Wasserman, Spencer Emtage, Stephen K. Burley, Siegfried H. Reich

Research output: Contribution to journalArticlepeer-review

104 Scopus citations


The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics. Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers. In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated. Several classes of ATP-competitive inhibitor have been described, which inhibit MET but also other kinases. Here, we describe SGX523, a novel,ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited METwith an IC50 of 4 nmol/L and is >1,000-fold selective versus the >200-fold selectivity of other protein kinases tested in biochemical assays. Crystallographic study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the selectivity. SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concentrations but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concentrations. SGX523 inhibition of MET in vivo was associated with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity. Our results show that SGX523 is the most selective inhibitor of MET catalytic activity described to date and is thus a useful tool to investigate the role of MET kinase in cancer without the confounding effects of promiscuous protein kinase inhibition.

Original languageEnglish (US)
Pages (from-to)3181-3190
Number of pages10
JournalMolecular cancer therapeutics
Issue number12
StatePublished - Dec 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo'. Together they form a unique fingerprint.

Cite this